Core Viewpoint - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has approved the establishment of a joint venture in synthetic biology to enhance management efficiency and decision-making capabilities [1][2]. Group 1: Joint Venture Details - The joint venture will be established between Hai Zheng Pharmaceutical and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., along with its Hong Kong subsidiary, Huizheng International [1]. - Hai Zheng Pharmaceutical plans to contribute 260 million RMB, representing 74.29% of the registered capital, while Huizheng International will contribute 90 million RMB, accounting for 25.71% [2]. - The market value of the assets involved in the investment, as of May 31, 2025, is approximately 243.78 million RMB, and the company will use the taxable value of the physical assets as its contribution [2]. Group 2: Operational Structure - The joint venture will have a board of directors elected by the shareholders' meeting, which is the highest authority of the joint venture [2]. - The joint venture will appoint one manager, who will be hired or dismissed by the board of directors [2]. - The management team is authorized to handle the establishment and asset contribution of the new company, including signing contracts and completing registration [3].

证券代码：600267 证券简称：海正药业 公告编号：临 2025-36 号 浙江海正药业股份有限公司 第十届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"或"海正药业"）第十届董 事会第四次会议于 2025 年 6 月 19 日（周四）以通讯方式召开，应参加会议董事 9 人，亲自参加会议董事 9 人。本次会议的召开程序符合《公司法》和《公司章 程》的规定，会议合法有效。本次会议由公司董事长肖卫红先生主持，经审议， 与会董事以通讯表决方式审议通过了《关于投资成立合成生物学合资公司的议 案》： 注：实际出资方式可能根据实际情况进行调整。 5、企业性质：有限责任公司（港澳台投资、非独资） 6、经营年限：长期 为进一步优化管理体系、提升决策效率，同意公司与全资子公司瀚晖制药有 限公司之香港全资子公司辉正国际有限公司（以下简称"辉正国际"）合资设立 合成生物学独立子公司，实现资源整合和集中管理，结合辉正国际在香港的平台 优势，为公司合成生物学业务的专业化、规模化发展 ...

Core Viewpoint - The animal vaccine sector has shown a positive performance with a 1.29% increase, ranking 10th among concept sectors, driven by significant gains in stocks like *ST Xianfeng, Kexing Pharmaceutical, and Jinhai Biological [1][2]. Group 1: Sector Performance - As of June 10, the animal vaccine concept saw 16 stocks rise, with *ST Xianfeng hitting the daily limit, while Kexing Pharmaceutical and Jinhai Biological increased by 6.40% and 4.72% respectively [1]. - The sector's performance is part of a broader market trend, with various other concepts also experiencing fluctuations, such as the transgenic sector rising by 3.15% [2]. Group 2: Capital Flow - The animal vaccine sector attracted a net inflow of 150 million yuan, with 10 stocks receiving significant capital inflows, and 7 stocks exceeding 10 million yuan in net inflow [2]. - Jinhai Biological led the net inflow with 67.34 million yuan, followed by Kexing Pharmaceutical and Dabeinong with 36.46 million yuan and 21.42 million yuan respectively [2][3]. Group 3: Stock-Specific Data - The top stocks by net capital inflow ratio included *ST Xianfeng at 10.73%, Kexing Pharmaceutical at 9.86%, and Jinhai Biological at 8.93% [3]. - The trading volume and turnover rates for key stocks indicate active trading, with Jinhai Biological showing a turnover rate of 15.46% and Kexing Pharmaceutical at 3.35% [3].

Company Overview - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has received approval for its new veterinary drug, non-rocoxib chewable tablets, which are designed to alleviate pain and inflammation in dogs [1] - The approval of this drug marks a significant milestone in the company's strategic positioning within the veterinary medicine sector, enhancing its market competitiveness [1] Business Development - Hai Zheng Pharmaceutical has been focusing on the pet medicine sector, transitioning from its original emphasis on economic animals since 1992, and has made notable progress in recent years [2] - As of the end of 2024, the company operates two production bases with 25 production lines and has over 40 products with 71 approved registration numbers [2] - The company's e-commerce performance has surpassed 100 million yuan in 2024, with a cumulative growth of 11 times over five years, indicating a strong expansion in its pet medicine business [2] Financial Performance - In 2024, the revenue from anti-parasitic and veterinary products reached 713 million yuan, reflecting a year-on-year decline of 14.07%, although the gross profit margin increased by 1.55 percentage points due to improved cost control [2] - Despite not yet achieving profitability, the subsidiary Hai Zheng Animal Health reported a revenue increase of 3.21% to 410 million yuan [2][3] Industry Trends - The pet medical industry in China is experiencing rapid growth, with the market size reaching 94 billion yuan in 2024, a year-on-year increase of 14.49% [4] - The approval of 52 new pet drugs by the Ministry of Agriculture and Rural Affairs in 2024, with 31 being domestically produced, indicates a significant enhancement in domestic drug development capabilities [4] - The integration of AI technology in the pet medical field, exemplified by the launch of the Vet1 AI model, represents a breakthrough in the industry [4] Future Outlook - The pet medical market is expected to continue expanding as pet owners increasingly prioritize their pets' health, driven by technological advancements and new medical models [5] - Companies are encouraged to leverage opportunities through innovation, service upgrades, and strategic partnerships to enhance competitiveness and promote sustainable industry growth [6]

Core Points - Zhejiang Haizheng Pharmaceutical Co., Ltd. has completed the registration capital and business scope changes, and has obtained a new business license [1][2] - The changes were approved during the 35th meeting of the 9th Board of Directors on March 27, 2025, and at the annual shareholders' meeting on April 18, 2025 [1] - The updated business license includes a broader range of activities, including the production and sale of pharmaceutical excipients, veterinary drugs, cosmetics, health foods, and food additives [1] Summary by Category Company Changes - The company has successfully completed the business registration changes and the filing of the revised Articles of Association [1] - The new business license was issued by the Zhejiang Provincial Market Supervision Administration [1] Business Scope - The revised business scope now includes the production of traditional Chinese medicine, pharmaceutical excipients, veterinary drugs, cosmetics, health foods, and food additives [1] - The company is also authorized to engage in the wholesale of pharmaceuticals and the import and export of drugs [1] Additional Activities - The company can now conduct research and development in biological chemical products, provide technical services, and engage in various sales activities related to chemical products and health foods [1]

证券代码：600267 证券简称：海正药业 公告编号：临 2025-34 号 浙江海正药业股份有限公司 关于子公司获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）控股子公司浙江海 正动物保健品有限公司（以下简称"海正动保公司"）收到中华人民共和国农业 农村部核准签发的非罗考昔咀嚼片《新兽药注册证书》，该新兽药产品正式获批 二类新兽药。现就相关情况公告如下： 一、新兽药的基本情况 新兽药名称：非罗考昔咀嚼片 研制单位：浙江海正动物保健品有限公司等 11 家公司 二、新兽药其他相关情况 非罗考昔咀嚼片是海正动保公司等 11 家公司共同研制获批的二类新兽药。 非罗考昔咀嚼片适用于缓解犬骨关节炎及临床手术等引起的疼痛和炎症。 2022 年 6 月，中华人民共和国农业农村部受理了海正动保公司与其他单位 联合递交的非罗考昔咀嚼片的新兽药注册申请。 截至目前，公司通过公开渠道未能获得市场其他公司上述同类产品具体销售 收入数据。 三、风险提示 本次海正动保公司非罗考昔 ...

浙江海正药业股份有限公司 关于完成注册资本、经营范围变更并换发营业执照的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600267 证券简称：海正药业 公告编号：临 2025-35 号 7、住所：浙江省台州市椒江区外沙路46号 8、经营范围：许可项目：药品生产（不含中药饮片的蒸、炒、炙、煅等炮 制技术的应用及中成药保密处方产品的生产）；药用辅料生产；药用辅料销售； 药品批发；兽药生产；兽药经营；药品进出口；化妆品生产；保健食品生产；食 品添加剂生产；饲料添加剂生产(依法须经批准的项目，经相关部门批准后方可 开展经营活动，具体经营项目以审批结果为准)。一般项目：化工产品生产（不 2、统一社会信用代码：91330000704676287N 3、注册资本：壹拾壹亿玖仟捌佰捌拾肆万捌仟壹佰玖拾陆元 4、类型：其他股份有限公司（上市） 5、成立日期：1998年02月11日 含许可类化工产品）；化工产品销售（不含许可类化工产品）；食品添加剂销售； 专用化学产品制造（不含危险化学品）；专用化学产品销售（不含危险化学品）； ...

Core Viewpoint - Haizheng Pharmaceutical (600267) announced that its subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the new veterinary drug registration certificate for Nirocoxib Chewable Tablets, officially classified as a Class II new veterinary drug [1] Group 1 - The new veterinary drug, Nirocoxib Chewable Tablets, is intended for alleviating pain and inflammation caused by canine osteoarthritis and clinical surgeries [1] - The registration application for Nirocoxib Chewable Tablets was submitted in June 2022, and it was processed by the Ministry of Agriculture and Rural Affairs along with other entities [1] - The product is now ready for production and will be launched once it obtains the veterinary product approval number, but it is not expected to have a significant impact on the company's performance in the short term [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600267 证券简称：海正药业 公告编号：临2025-33号 浙江海正药业股份有限公司 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，现将公司第四次以集中竞价交易方式回购股份的进展情况公告如下： 关于第四次以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 浙江海正药业股份有限公司（以下简称"公司"）于2025年5月12日召开的第十届董事会第二次会议和第 十届监事会第二次会议，审议通过了《关于第四次以集中竞价交易方式回购公司股份的议案》，同意公 司通过自有资金以集中竞价交易方式回购公司股份，回购的资金总额不低于人民币5千万元且不超过人 民币1亿元（均包含本数），回购股份价格不超过人民币13元/股（含），回购期限自公司董事会审议通 过回购股份方案之日起12个月内。具体内容详见《浙江海正药业股份有限公司关于第四次以集中竞价交 易方式回购股 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600267 证券简称：海正药业 公告编号：临 2025-33 号 浙江海正药业股份有限公司 关于第四次以集中竞价交易方式回购公司股份的进展 公告 截至 2025 年 5 月月底，公司已累计回购股份 1,347,000 股，占公司总股本的 比例为 0.11%，购买的最高价为 9.22 元/股、最低价为 8.92 元/股，已支付的总金额 为 12,249,660.00 元（不含交易费用）。 重要内容提示： | 回购方案首次披露日 | 2025/5/13 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 5 月 5 | 12 | 日~2026 | 年 | 月 | 11 日 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | ...